Impact of postnatal dexamethasone on psychotomimetic effects of MK-801 measured on adult rats

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1034-1041

  Wȩdzony, Krzysztof ^a   Markowicz Kula, Katarzyna ^a   Fijał, Agnieszka Chocyk Katarzyna ^a   Przyborowska, Aleksandra ^a   Maćkowiak, Marzena ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Locomotor activity; MK 801; Postnatal dexamethasone; Sensorimotor gating

Indexed keywords

DEXAMETHASONE; DIZOCILPINE; PSYCHEDELIC AGENT;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; LOCOMOTION; MALE; NONHUMAN; PERINATAL PERIOD; PSYCHOSIS; RAT; SENSORIMOTOR FUNCTION; STARTLE REFLEX;

EID: 76049088133     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70165-3     Document Type: Article

References (29)

1. Bakker JM, Kavelaars A, Kamphuis PJ, Cobelens PM, van Vugt HH, Van Bel F, Heijnen CJ: Neonatal dexamethasone treatment increases susceptibility to experimental autoimmune disease in adult rats. J Immunol, 2000, 165, 5932-5937.
2. Bakker JM, Van Bel F, Heijnen CJ: Neonatal glucocorticoids and the developing brain: short-term treatment with life-long consequences? Trends Neurosci, 2001, 24, 649-653.
3. Bakshi VP, Geyer MA: Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDAantagonist dizocilpine. J Neurosci, 1998, 18, 8394-8401.
4. Beck JC, Johnson JW: Maternal administration of glucocorticoids. Clin Obstet Gynecol, 1980, 23, 93-113.
5. Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C: Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev, 2008, 32, 1014-1023.
6. Cummings JJ, D'Eugenio DB, Gross SJ: A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med, 1989, 320, 1505-1510.
7. De Kloet ER, Reul JM, Sutanto W: Corticosteroids and the brain. J Steroid Biochem Mol Biol, 1990, 37, 387-394.
8. Diaz R, Brown RW, Seckl JR: Distinct ontogeny of glucocorticoid and mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase types I and II mRNAs in the fetal rat brain suggest a complex control of glucocorticoid actions. J Neurosci, 1998, 18, 2570-2580.
9. Dobbing J, Sands J: Comparative aspects of the brain growth spurt. Early Hum Dev, 1979, 3, 79-83.
10. Finer NN, Craft A, Vaucher YE, Clark RH, Sola A: Postnatal steroids: short-term gain, long-term pain? J Pediatr, 2000, 137, 9-13.
11. Fone KC, Porkess MV: Behavioural and neurochemical effects of post-weaning social isolation in rodentsrelevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev, 2008, 32, 1087-1102.
12. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR: Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl), 2001, 156, 117-154.
13. Hauser J, Feldon J, Pryce CR: Prenatal dexamethasone exposure, postnatal development, and adulthood prepulse inhibition and latent inhibition in Wistar rats. Behav Brain Res, 2006, 175, 51-61.
14. Javitt DC: Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry, 1987, 9, 12-35.
15. Kamphuis PJ, Croiset G, Bakker JM, Van Bel F, Van Ree JM, Wiegant VM: Neonatal dexamethasone treatment affects social behaviour of rats in later life. Neuropharmacology, 2004, 47, 461-474.
16. Kilts CD: The changing roles and targets for animal models of schizophrenia. Biol Psychiatry, 2001, 50, 845-855.
17. Lipska BK, Weinberger DR: To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology, 2000, 23, 223-239.
18. Lugo RA, Nahata MC, Menke JA, McClead RE, Jr.: Pharmacokinetics of dexamethasone in premature neonates. Eur J Clin Pharmacol, 1996, 49, 477-483.
19. Lupien SJ, McEwen BS: The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Brain Res Rev, 1997, 24, 1-27.
20. McArthur S, McHale E, Gillies GE: The size and distribution of midbrain dopaminergic populations are permanently altered by perinatal glucocorticoid exposure in a sex- region- and time-specific manner. Neuropsychopharmacology, 2007, 32, 1462-1476.
21. Millen KJ, Millonig JH, Wingate RJ, Alder J, Hatten ME: Neurogenetics of the cerebellar system. J Child Neurol, 1999, 14, 574-581.
22. Raff H: Neonatal dexamethasone therapy: short- and long-term consequences. Trends Endocrinol Metab, 2004, 15, 351-352.
23. Rahimi O, Claiborne BJ: Morphological development and maturation of granule neuron dendrites in the rat dentate gyrus. Prog Brain Res, 2007, 163, 167-181.
24. Sanfacon R, Possmayer F, Harding PG: Dexamethasone treatment of the guinea pig fetus: its effects on the incorporation of H-thymidine into deoxyribonucleic acid. Am J Obstet Gynecol, 1977, 127, 745-752.
25. Slotkin TA, Kreider ML, Tate CA, Seidler FJ: Critical prenatal and postnatal periods for persistent effects of dexamethasone on serotonergic and dopaminergic systems. Neuropsychopharmacology, 2006, 31, 904-911.
26. Wȩdzony K, Fijał K, Maćkowiak M, Chocyk A: Detrimental effect of postnatal blockade of N-methyl-Daspartate receptors on sensorimotor gating is reversed by neuroleptic drugs. Pharmacol Rep, 2008, 60, 856-864.
27. Wȩdzony K, Gołembiowska K, Zazula M: Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmiedebergs Arch Pharmacol, 1994, 350, 555-562.
28. Wȩdzony K, Ma̧kowiak M, Zaja̧czkowski W, Fijał K, Chocyk A, Czyrak A: WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology, 2000, 23, 547-559.
29. Weinstock M: Alterations induced by gestational stress in brain morphology and behaviour of the offspring. Prog Neurobiol, 2001, 65, 427-451.